Scarica l'app Stockscreener
491.64
0.06%
0.305
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$491.34
Aprire:
$495.83
Volume 24 ore:
71,387
Relative Volume:
0.05
Capitalizzazione di mercato:
$124.83B
Reddito:
$12.34B
Utile/perdita netta:
$4.34B
Rapporto P/E:
29.15
EPS:
16.8685
Flusso di cassa netto:
$3.71B
1 W Prestazione:
+5.32%
1M Prestazione:
+9.85%
6M Prestazione:
+6.92%
1 anno Prestazione:
+11.40%
Intervallo 1D:
$487.62
$497.00
Intervallo di 1 settimana:
$463.75
$503.89
Portata 52W:
$362.50
$507.92
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
491.82 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
631.87 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
897.76 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.99 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.41 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Aggiornamento | Maxim Group | Hold → Buy |
| 2026-03-10 | Iniziato | Jefferies | Buy |
| 2026-03-10 | Reiterato | Oppenheimer | Outperform |
| 2026-02-13 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Vertex Pharma enters Russell 1000 value, shares reflect mixed benchmark shift - AD HOC NEWS
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell 1000 Value Benchmark - marketscreener.com
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Growth Benchmark - marketscreener.com
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com
Vertex Pharma analyst optimism builds ahead earnings week, shares trade near recent high - Ad-hoc-news.de
Price to book forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
Price to earnings forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
Vertex Pharma strategy in cystic fibrosis, shares anchored in the NASDAQ-100 healthcare field - Ad-hoc-news.de
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 26 June - Investing.com UK
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to EBIT forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Price to sales forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
VRTX (NASDAQ) affiliate files Form 144: 596 shares vest, multiple sales by Carmen R. Bozic - Stock Titan
Enterprise value to revenue forward of Vertex Pharmaceuticals Incorporated – NASDAQ:VRTX - TradingView
Vertex Pharmaceuticals Incorporated Actuals & Estimates (NASDAQ:VRTX) - TradingView
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Vertex Pharma leads biotech this week, shares hover near record highs - Ad-hoc-news.de
Fierce Biotech Layoff Tracker 2026: Biogen sheds Apellis R&D roles; ADC Tx slims workforce - Fierce Biotech
Vertex Pharmaceuticals Incorporated Actuals & Estimates (BMV:VRTX) - TradingView
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Why Vertex Pharmaceuticals (NASDAQ:VRTX) Is Drawing Fresh Attention? - Kalkine Media
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals: Povetacicept May Redefine Growth Narrative (Rating Upgrade) (VRTX) - Seeking Alpha
Is Vertex Pharmaceuticals Successfully Diversifying Beyond Cystic Fibrosis - Kavout | AI
Former Vertex, GSK exec launches science-first pet nutrition company - The Business Journals
Vertex Pharmaceuticals Inc (VRTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
A Loophole Brings Cystic Fibrosis Patients a ‘Miracle Drug’ in Generic Form - The New York Times
Vertex (VRTX) EVP and CMO Carmen Bozic sells 1,020 shares under 10b5-1 plan - Stock Titan
Vertex Pharma with clear analyst backing, shares supported by strong consensus estimates - Ad-hoc-news.de
Vertex Pharmaceuticals (VRTX) Stock After Strong Multi‑Year Run Is The Price Still Reasonable - Yahoo Finance
Positive Pediatric CASGEVY Data Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX) - Yahoo Finance
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda - GlobeNewswire Inc.
Vertex Pharmaceuticals (NASDAQ:VRTX): A GARP Growth Stock with Reasonable Valuation and Strong Fundamentals - ChartMill
Vertex Pharmaceuticals Inc (VRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vertex Pharmaceuticals Inc (VRTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Up by 3.45% on Jun 22: What Signal Does It Send? - TradingKey
2 Reasons to Like VRTX (and 1 Not So Much) - Yahoo Finance
Barclays Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $615 - Moomoo
How Strong Pediatric CASGEVY Data Could Impact Vertex Pharmaceuticals’ (VRTX) Gene Therapy Investment Narrative - simplywall.st
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks. - The Motley Fool
Vertex Pharma Stockweekly review in a strong biotech sector - Ad-hoc-news.de
Can Vertex's Kidney Pipeline Power Its Next Growth Phase? - TradingView
Nia Impact Solutions Fund's Vertex Pharmaceuticals Inc(VRTX) Holding History - GuruFocus
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock - Yahoo Finance
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):